Screening of dermatology drugs for aberrant use‐patterns: An application of epidemiologic estimates and measures of inequality in drug use
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16037 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Thomas Delvin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health, University of Southern Denmark, Odense C, Denmark. Hauptthemen laut MEDLINE: Registries, Dermatologic Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Dermatology treatments require adherence for safe and effective use. Real‐world healthcare databases can reveal drug utilization patterns and uncover inappropriate or unexpected use. This study aimed to analyse dermatology drug utilization patterns using epidemiological and inequality measures, leveraging Danish nationwide registries. It also assessed the feasibility of this method for detecting aberrant drug use.
Methods
We formed a 2019 cohort of all patients treated for skin conditions through Danish healthcare registries. We calculated prevalence, incidence rates and treatment duration for dermatological drugs. Inequality in drug utilization was assessed using Lorenz curves, Gini coefficients and other measures.
Results
The study encompassed 1 021 255 patients using 94 dermatology drugs. Most usage aligned with ‘expected clinical use’, but we detected inequality, with some drugs having high Gini coefficients and disproportionate consumption by the top percentile of users. Notable findings included potential inappropriate antibiotic use, excessive topical corticosteroid use and unexpected drug use duration.
Conclusions
In Denmark, dermatology drugs are used primarily as anticipated, with minimal unexpected patterns. Specific follow‐up is required to draw conclusions about inappropriate use. This approach demonstrates broad applicability for screening aberrant drug utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health, University of Southern Denmark, Odense C, Denmark.
- R&D Medical Sciences, LEO Pharma, Ballerup, Denmark.
- Clinical Institute, University of Southern Denmark, Odense C, Denmark.
- Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark.
ORCID-Profile: Thomas Delvin
Zitieren
APA
Delvin, T., Bygum, A., Lund, L. C., Andersen, J. H., & Hallas, J. (2024). Screening of dermatology drugs for aberrant use‐patterns: An application of epidemiologic estimates and measures of inequality in drug use. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16037
Vancouver
Delvin T, Bygum A, Lund LC, Andersen JH, Hallas J. Screening of dermatology drugs for aberrant use‐patterns: An application of epidemiologic estimates and measures of inequality in drug use. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16037
BibTeX
@article{Delvin2024,
author = {Delvin, Thomas and Bygum, Anette and Lund, Lars Christian and Andersen, Jacob Harbo and Hallas, Jesper},
title = {Screening of dermatology drugs for aberrant use‐patterns: An application of epidemiologic estimates and measures of inequality in drug use},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16037}
}
EUVIMED